Treatment of relapsed/refractory acute lymphoblastic leukemia.

Treatment of relapsed/refractory acute lymphoblastic leukemia. Clin Adv Hematol Oncol. 2019 Mar;17(3):166-175 Authors: Paul S, Rausch CR, Nasnas PE, Kantarjian H, Jabbour EJ Abstract Patients with relapsed or refractory acute lymphoblastic leukemia (R/R ALL) have dismal outcomes, with survival of less than 6 months, and treatment options in the salvage setting have been limited to conventional cytotoxic chemotherapy with minimal activity. Advances in the development of novel targeted therapies have significantly improved outcomes in R/R ALL. Blinatumomab, inotuzumab ozogamicin, and chimeric antigen receptor (CAR) T-cell therapy constitute new treatment modalities that are challenging the historical regimens and paving a new path for treating patients with R/R ALL. PMID: 30969955 [PubMed - in process]
Source: Clinical Advances in Hematology and Oncology - Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research